Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain.

Clinicoecon Outcomes Res · 2015 · PMC4461091 · PMID 26082655

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significanceP =0.075so close (0.05 < p ≤ 0.1)

The costs incurred in primary care were responsible for a portion of this difference in cost between brand and generic (€855 vs €722; P <0.001), while the differences observed in specialist care did not reach statistical significance ( P =0.075).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.